Compare ABCB & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABCB | MIRM |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | ABCB | MIRM |
|---|---|---|
| Price | $79.98 | $100.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $79.57 | ★ $100.09 |
| AVG Volume (30 Days) | 462.1K | ★ 781.6K |
| Earning Date | 01-29-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 20.70 | N/A |
| EPS | ★ 5.77 | N/A |
| Revenue | ★ $1,130,299,000.00 | $471,794,000.00 |
| Revenue This Year | $14.00 | $54.98 |
| Revenue Next Year | $5.02 | $21.94 |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | 7.96 | ★ 53.66 |
| 52 Week Low | $48.27 | $36.88 |
| 52 Week High | $83.64 | $99.44 |
| Indicator | ABCB | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 78.38 |
| Support Level | $79.33 | $89.47 |
| Resistance Level | $83.64 | $93.70 |
| Average True Range (ATR) | 2.01 | 4.14 |
| MACD | 0.01 | 0.83 |
| Stochastic Oscillator | 45.52 | 97.18 |
Ameris Bancorp is a bank holding company that operates through Ameris Bank, its subsidiary. The company operates branches in Georgia, Alabama, Florida, and South Carolina. It offers traditional banking services such as business banking, personal banking, checking, savings, mobile banking, and others. The bank is organized into four segments: the Banking Division, the Retail Mortgage Division, the Warehouse Lending Division and the Premium Finance Division. The company generates majority of its revenue from the banking division. Ameris intends to acquire banks in its geographic region to increase its market share and expand beyond its current market.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.